High-resolution cryo-EM of the human CDK-activating kinase for structure-based drug design.
Cushing, V.I., Koh, A.F., Feng, J., Jurgaityte, K., Bondke, A., Kroll, S.H.B., Barbazanges, M., Scheiper, B., Bahl, A.K., Barrett, A.G.M., Ali, S., Kotecha, A., Greber, B.J.(2024) Nat Commun 15: 2265-2265
- PubMed: 38480681 
- DOI: https://doi.org/10.1038/s41467-024-46375-9
- Primary Citation of Related Structures:  
8ORM, 8P6V, 8P6W, 8P6X, 8P6Y, 8P6Z, 8P70, 8P71, 8P72, 8P73, 8P74, 8P75, 8P76, 8P77, 8P78, 8P79, 8P7L, 8PLZ - PubMed Abstract: 
Rational design of next-generation therapeutics can be facilitated by high-resolution structures of drug targets bound to small-molecule inhibitors. However, application of structure-based methods to macromolecules refractory to crystallization has been hampered by the often-limiting resolution and throughput of cryogenic electron microscopy (cryo-EM). Here, we use high-resolution cryo-EM to determine structures of the CDK-activating kinase, a master regulator of cell growth and division, in its free and nucleotide-bound states and in complex with 15 inhibitors at up to 1.8 Å resolution. Our structures provide detailed insight into inhibitor interactions and networks of water molecules in the active site of cyclin-dependent kinase 7 and provide insights into the mechanisms contributing to inhibitor selectivity, thereby providing the basis for rational design of next-generation therapeutics. These results establish a methodological framework for the use of high-resolution cryo-EM in structure-based drug design.
Organizational Affiliation: 
The Institute of Cancer Research, Chester Beatty Laboratories, 237 Fulham Road, London, SW3 6JB, UK.